An antagonist of troglitazone-induced PPARγ transcriptional activity (IC50 = 140 μM); selective for PPARγ, not affecting basal or agonist-induced transcriptional activity of PPARα, PPARβ, or FXR; inhibits PPARγ-dependent differentiation of adipocytes; decreases weight gained and white adipose tissue mass accumulated when administered to mice at a dose of 400 mg/kg for ten weeks; protects against high-fat diet-induced insulin resistance in wild-type mice; improves insulin sensitivity in ob/ob mice